Corneal stroma can clear LASIK contamination

Article

The corneal stroma has the ability to clear microorganisms introduced during LASIK.

The corneal stroma has the ability to clear microorganisms introduced during LASIK, according to a study published in the October issue of the Journal of Cataract and Refractive Surgery.

Sepehr Feizi and colleagues from Labbafinejad Hospital, Shaheed Beheshti University and Baqyatallah Hospital, Tehran, Iran measured the rate of corneal interface contamination during LASIK to determine possible sources of contamination and evaluate how the cornea reacts.

A total of 200 eyes were evaluated for corneal interface contamination following LASIK. Cultures were taken from the upper and lower eyelid margins and the inferior fornices prior to surgery and from the corneal interface and the instrument at the end of surgery. Media were cultured for 14 days at 37°C under aerobic and anaerobic conditions.

The rate of contamination was recorded as 24.5%. The most commonly found organism was Staphylococcus epidermidis, which was found in 43 cases (87.7%). None of the contaminated or non-contaminated cases developed corneal ulcers, however, two eyes did develop diffuse lamellar keratitis.

The authors concluded that the corneal stroma is able to clear LASIK induced microorganisms.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.